Fig. 3From: PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcomaBEZ235 inhibits PI3K/mTOR pathway downstream effectors in LMS cells. Immunoblot demonstrates decreased levels of p-AKTS473 and of p-4EBP1T37/46 in total lysates from SKLMS1 and STS39 cells treated with BEZ235 for 72 h at concentrations ranging from 0 to 1000 nM/L. Total AKT, 4EBP1 and tubulin levels demonstrate equal loading of protein lysatesBack to article page